Cargando…

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study

OBJECTIVE: To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use. DESIGN: A phase 3, 24-week, multicenter, randomised, double-blind (DB), active-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizokami, Yuji, Oda, Kazunori, Funao, Nobuo, Nishimura, Akira, Soen, Satoshi, Kawai, Takashi, Ashida, Kiyoshi, Sugano, Kentaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Peptic Ulcer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969369/ https://www.ncbi.nlm.nih.gov/pubmed/28988197 http://dx.doi.org/10.1136/gutjnl-2017-314010

Ejemplares similares

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study
por: Kawai, Takashi, et al.
Publicado: (2018)

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
por: Ashida, Kiyoshi, et al.
Publicado: (2018)

Discussion: Current Clinical Management of Peptic Ulcer Disease
por: Berlin, Roger G.
Publicado: (1992)

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
por: Sugano, Kentaro, et al.
Publicado: (2012)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
por: Xiao, Yinglian, et al.
Publicado: (2020)

Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions
por: van den Broek, F J C, et al.
Publicado: (2008)

Recent Teaching on Their Surgical Diagnosis and Treatment
Publicado: (1920)

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open
por: Panaccione, Remo, et al.
Publicado: (2022)

Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non‐inferiority randomised controlled trials
por: Miwa, H., et al.
Publicado: (2016)

Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan
por: Habu, Yasuki
Publicado: (2019)

Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial
por: Kawai, Daisuke, et al.
Publicado: (2021)

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
por: Sugano, Kentaro, et al.
Publicado: (2011)

Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers
por: Takahashi, Kazuya, et al.
Publicado: (2016)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022)

Prevention of NSAID-Induced Small Intestinal Mucosal Injury: Prophylactic Potential of Lansoprazole
por: Higuchi, Kazuhide, et al.
Publicado: (2009)

Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study
por: Ohkuma, Kanji, et al.
Publicado: (2018)

Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study
por: Ban, Hiromitsu, et al.
Publicado: (2021)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2016)

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
por: Sandborn, William J., et al.
Publicado: (2021)

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
por: Iwakiri, Katsuhiko, et al.
Publicado: (2017)

Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2019)

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
por: Sugano, Kentaro
Publicado: (2018)

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

The Expression of Heme Oxygenase-1 Induced by Lansoprazole
por: Takagi, Tomohisa, et al.
Publicado: (2009)

Gastroduodenal Intussusception Due to Vonoprazan-induced Gastric Polyps
por: Nishimura, Naoyuki, et al.
Publicado: (2021)

Cefazolin-Gentamicin versus Vancomycin-Ceftazidime Eye Drops for Bacterial Corneal Ulcers;a Randomized Clinical Trial
por: Dehghani, Ali-Reza, et al.
Publicado: (2009)

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
por: Osterman, Mark T., et al.
Publicado: (2019)

Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls – a prospective cohort study
por: Reijntjes, Maud A., et al.
Publicado: (2022)

Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease
por: Tabuchi, Maiko, et al.
Publicado: (2021)

Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity
por: Wakai, Eri, et al.
Publicado: (2022)

Immune and Inflammatory Responses in GERD and Lansoprazole
por: Isomoto, Hajime, et al.
Publicado: (2007)

Toxic epidermal necrolysis induced by lansoprazole()
por: Fracaroli, Tainá Scalfoni, et al.
Publicado: (2013)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients
por: Suzuki, Yoshiharu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k5qhlrug16n8l8s2n7228rhgrv